Prof Phil McFarlane for Sir Alister McIntyre Distinguished Lecture and Award
NOTED CANADIAN nephrologist (kidney specialist), Professor Phil McFarlane, is the 2019 nominee for the Sir Alister McIntyre Distinguished Award. He will receive his award at the 25th Annual International Diabetes Conference on Friday, April 26 at the Jewel Resort, Runaway Bay.
The University Diabetes Outreach Programme (UDOP), organisers of the conference, has recognised him for distinguished services internationally in diabetes and kidney diseases.
Following receipt of the award and a citation, Dr McFarlane will present the Sir Alister McIntyre Distinguished Lecture. His title is: Diagnosing and treating chronic kidney disease in people with diabetes.
Dr McFarlane, who has an MD, a PhD and FRCP (C) among other credentials, is a clinical investigator in the Division of Nephrology at St Michael’s Hospital in Toronto, and an assistant professor at the University of Toronto. At St Michael’s, he is the Medical Director of Home Dialysis and the Chief Nephrologist in the Live Kidney Donor Programme.
PUBLICATIONS
UDOP’s 2019 Sir Alister McIntyre Distinguished awardee is widely published and cited. He has an H-Index of 30 as of April 25, 2018, with 3,277 citations. He has published over 100 peer-reviewed manuscripts and several book chapters.
Dr McFarlane has contributed to scores of peer-reviewed articles in well-known journals. These articles include the role of sodium glucose co-transporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes, (Curr Med Res Opin, February 2019); thrombosis and kidney disease in cancer: comorbidities defining a very highrisk patient: A position paper from the Cancer & the Kidney International
Network (Journal of OncoNephrology, November 2018).
Dr McFarlane’s research interests include health economics and outcomes research.
He is the primary holder of many prestigious research grants, among them: $200,000 for research on the Effectiveness of Multidisciplinary Diabetes Care, (Sanofi-Aventis, 20052006); the St Michael’s Hospital Clinical Nephrology Research Unit Infrastructure Grant of $400,000 (Ortho-Biotech Canada, (2005, 2006), and cost-effectiveness of home nocturnal hemodialysis (Kidney Foundation of Canada Fellowship, $45,425/year 1999-2002).
COMMITTEES
Dr McFarlane has served on a number of committees: the American Journal of Kidney Diseases (2003, 2008, 2009); American Journal of Transplantation (2008); Applied Health Economics and Health Policy, (2008); Canadian Research Awards. Membership:
Prof. McFarlane is a member of the Diabetes Canada Clinical Practice Guidelines Group, the Canadian Society of Nephrology Guideline Group, and the Hypertension Canada Guideline Group.
He is currently the Provincial Medical Lead for dialysis access and home hemodialysis.